THE_HIGHLANDS_PHARMACY_LI - Accounts

Company registration number 06521889 (England and Wales)
THE HIGHLANDS PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023
PAGES FOR FILING WITH REGISTRAR
THE HIGHLANDS PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
THE HIGHLANDS PHARMACY LIMITED
BALANCE SHEET
AS AT
30 JUNE 2023
30 June 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Tangible assets
4
16,338
20,040
Current assets
Stocks
59,422
61,121
Debtors
5
185,153
158,774
Cash at bank and in hand
49,222
160,957
293,797
380,852
Creditors: amounts falling due within one year
6
(262,701)
(281,742)
Net current assets
31,096
99,110
Net assets
47,434
119,150
Capital and reserves
Called up share capital
50
50
Profit and loss reserves
47,384
119,100
Total equity
47,434
119,150

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 11 March 2024 and are signed on its behalf by:
Mr K W K Man
Director
Company registration number 06521889 (England and Wales)
THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023
- 2 -
1
Accounting policies
Company information

The Highlands Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is The Surgery, Highlands, Flitwick, Bedford, MK45 1DW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment
20% reducing balance
Computer equipment
25% reducing balance
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
1
Accounting policies
(Continued)
- 3 -
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
1
Accounting policies
(Continued)
- 4 -
1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
16
16
THE HIGHLANDS PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
- 5 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 July 2022
160,366
Additions
850
At 30 June 2023
161,216
Depreciation and impairment
At 1 July 2022
140,326
Depreciation charged in the year
4,552
At 30 June 2023
144,878
Carrying amount
At 30 June 2023
16,338
At 30 June 2022
20,040
5
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
149,833
123,657
Corporation tax recoverable
5,160
-
0
Other debtors
30,160
35,117
185,153
158,774
6
Creditors: amounts falling due within one year
2023
2022
£
£
Trade creditors
223,989
237,442
Corporation tax
-
0
5,160
Other taxation and social security
7,067
6,971
Other creditors
31,645
32,169
262,701
281,742

 

2023-06-302022-07-01false11 March 2024CCH SoftwareCCH Accounts Production 2023.300No description of principal activityDr W T de GrootMr P SharrattMr K W K ManMrs S BakerDr S D ShortMrs P A Lingfalse065218892022-07-012023-06-30065218892023-06-30065218892022-06-3006521889core:OtherPropertyPlantEquipment2023-06-3006521889core:OtherPropertyPlantEquipment2022-06-3006521889core:CurrentFinancialInstrumentscore:WithinOneYear2023-06-3006521889core:CurrentFinancialInstrumentscore:WithinOneYear2022-06-3006521889core:CurrentFinancialInstruments2023-06-3006521889core:CurrentFinancialInstruments2022-06-3006521889core:ShareCapital2023-06-3006521889core:ShareCapital2022-06-3006521889core:RetainedEarningsAccumulatedLosses2023-06-3006521889core:RetainedEarningsAccumulatedLosses2022-06-3006521889bus:Director32022-07-012023-06-3006521889core:FurnitureFittings2022-07-012023-06-3006521889core:ComputerEquipment2022-07-012023-06-30065218892021-07-012022-06-3006521889core:OtherPropertyPlantEquipment2022-06-3006521889core:OtherPropertyPlantEquipment2022-07-012023-06-3006521889core:WithinOneYear2023-06-3006521889core:WithinOneYear2022-06-3006521889bus:PrivateLimitedCompanyLtd2022-07-012023-06-3006521889bus:SmallCompaniesRegimeForAccounts2022-07-012023-06-3006521889bus:FRS1022022-07-012023-06-3006521889bus:AuditExemptWithAccountantsReport2022-07-012023-06-3006521889bus:Director12022-07-012023-06-3006521889bus:Director22022-07-012023-06-3006521889bus:Director42022-07-012023-06-3006521889bus:Director52022-07-012023-06-3006521889bus:Director62022-07-012023-06-3006521889bus:FullAccounts2022-07-012023-06-30xbrli:purexbrli:sharesiso4217:GBP